Contribute Try STAT+ Today

Over the weekend, the world got some staggering and perhaps hopeful news. China’s equivalent of the FDA approved a new treatment for Alzheimer’s disease, one that’s meant to work by changing the human microbiome.

It goes without saying that any novel treatment for Alzheimer’s is a big deal. It’s been 17 years since the last new drug won approval and the disease affects millions of people around the world. But as the days went on and more details came to light, experts started picking at the data behind this new drug from China and spotting some red flags.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.